| Literature DB >> 35783657 |
Yang Jiang1,2, Shixin Qi1,2.
Abstract
Purpose: To evaluate the diagnostic value of spectral-domain optical coherence tomography (SD-OCT) for polypoidal choroidal vasculopathy (PCV).Entities:
Keywords: diagnostic value; meta-analysis; polypoidal choroidal vasculopathy; sensitivity; specificity; spectral-domain optical coherence tomography
Year: 2022 PMID: 35783657 PMCID: PMC9242399 DOI: 10.3389/fmed.2022.878946
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Literature retrieval flow chart.
Characteristics of the included studies (n = 12).
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Chaikitmongkol et al. ( | Thailand | 48/71 | nvAMD, | CFP+SD-OCT | ICGA | Spectralis OCT | 40 | 12 | 8 | 59 |
| Liu et al. ( | China | 113/75 | nvAMD | SD-OCT | FFA/ICGA | Spectralis HRA+OCT | 101 | 11 | 12 | 64 |
| Cheung et al. ( | Singapore | 23/27 | CNV, | SD-OCT | FFA/ICGA | Spectralis OCT | 19 | 13 | 4 | 14 |
| Yang et al. ( | China | 52/51 | nvAMD | CFP+ SD-OCT | FFA/ICGA | unclear | 46 | 4 | 6 | 47 |
| Chang et al. ( | Korea | 147/116 | nvAMD | SD-OCT | ICGA | Spectralis HRA+OCT | 132 | 18 | 15 | 98 |
| Laíns et al. ( | Portugal | 47/53 | occult CNV | SD-OCT | ICGA | Spectralis HRA+OCT and Cirrus HD-OCT | 32 | 23 | 15 | 30 |
| Chaikitmongkol et al. ( | Thailand | 65/59 | nvAMD, | CFP+ SD-OCT | FFA/ICGA | unclear | 62 | 3 | 3 | 56 |
| De Salvo et al. ( | United Kingdom | 37/14 | occult CNV | SD-OCT | FFA/ICGA | Spectralis HRA+OCT | 35 | 1 | 2 | 13 |
| Eraydin et al. ( | Turkey | 69/24 | dry-type AMD, nvAMD, | SD-OCT | ICGA | Spectralis HRA+OCT | 52 | 6 | 17 | 18 |
| Liao et al. | China | 24/38 | wAMD | SD-OCT | FFA/ICGA | unclear | 22 | 4 | 2 | 34 |
| Zhang et al. ( | China | 25/38 | wAMD | SD-OCT | FFA/ICGA | Cirrus HD-OCT 4000 | 23 | 4 | 2 | 34 |
| Xia et al. | China | 56/76 | wAMD | SD-OCT | FFA/ICGA | Spectralis HRA+OCT | 49 | 10 | 7 | 66 |
PCV, Polypoidal choroidal vasculopathy; nvAMD, neovascular age-related macular degeneration; wAMD, wet age-related macular degeneration; CSC, central serous chorioretinopathy; RAP, retinal angiomatous proliferation; CNV, choroidal neovascularization; PED, pigment epithelial detachment; ICGA, indocyanine green angiography; FFA, fundus fluorescein angiography; SD-OCT, spectral-domain optical coherence tomography; CFP, color fundus photography; Spectralis OCT, Heidelberg Engineering Inc., Heidelberg, Germany; Spectralis HRA+OCT, Heidelberg Engineering Inc., Heidelberg, Germany; Cirrus HD-OCT, Carl Zeiss Meditec Inc., Dublin, United States; Cirrus HD-OCT 4000, Carl Zeiss Meditec Inc., Dublin, United States; TP, true positives; FP, false positives; TN, true negatives; FN, false negatives.
Figure 2Bar chart of literature quality assessment.
Figure 3Summary of bias risk and clinical applicability. Figure 2 combined with Figure 3 together describe literature quality assessment.
Figure 4Meta-analysis forest plots of the relevant effect sizes. (A) The pooled sensitivity (Se). (B) The pooled specificity (Sp). (C) The pooled positive likelihood ratio (PLR). (D) The pooled negative likelihood ratio (NLR). (E) The pooled diagnostic odds ratio (DOR). (F) The summary receiver operating characteristic curve (sROC) and area under the curve (AUC).
Parameters of meta-regression analysis.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Race | 1.783 | 0.6346 |
| 5.95 | 1.42-24.99 |
| Sample size | −0.711 | 0.6652 | 0.3165 | 0.49 | 0.11–2.28 |
| Device type | 0.238 | 0.6619 | 0.7298 | 1.27 | 0.27–6.07 |
Indicates statistical significant P-values.
Parameters of subgroup analysis.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
| Asians ( | 0.89/(0.86–0.92) | 0.86/(0.82–0.88) | 6.28/(3.87–10.19) | 0.13/(0.10–0.16) | 49.01/(25.94–92.61) | 0.9531 |
| Caucasians ( | 0.78/(0.70–0.84) | 0.67/(0.56–0.77) | 2.92/(1.08–7.87) | 0.28/(0.12–0.67) | 12.30/(2.00–75.61) | 0.9021 |
|
| ||||||
| SD–OCT ( | 0.86/(0.83–0.89) | 0.80/(0.77–0.84) | 4.49/(2.59–7.79) | 0.18/(0.10–0.30) | 27.05/(10.47–69.89) | 0.9382 |
| SD-OCT + CFP ( | 0.90/(0.84–0.94) | 0.90/(0.84–0.94) | 9.27/(3.75–22.89) | 0.12/(0.06–0.25) | 85.02/(18.16–398.16) | 0.9622 |
|
| ||||||
| nvAMD ( | 0.89/(0.86–0.92) | 0.87/(0.83–0.90) | 6.78/(5.24–8.78) | 0.12/(0.09–0.16) | 55.87/(36.61–85.27) | 0.9488 |
| Others ( | 0.83/(0.78–0.87) | 0.77/(0.71–0.82) | 3.88/(1.82–8.28) | 0.21/(0.10–0.42) | 21.21/(5.26–85.54) | 0.9302 |
Se, sensitivity; Sp, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the sROC curve; 95%CI, 95% confidence interval; SD-OCT, spectral-domain optical coherence tomography; SD-OCT+CFP, spectral-domain optical coherence tomography combined with color fundus photography; nvAMD, neovascular age-related macular degeneration; others, inculding dry-type AMD, central serous chorioretinopathy, serous retinal pigment epithelial detachment, retinal angiomatous proliferation, choroidal neovascularization, idiopathic/occult choroidal neovascularization with and without nvAMD. n, number of included studies.
Figure 5Fagan's plot.
Figure 6Sensitivity analysis.
Figure 7Deeks' funnel plot.